Company Highlights

Patrys PAT-SM6 antibody detected in patient tumours

PAT-SM6 is a natural human antibody that has shown promise as a potential treatment for multiple types of cancer including melanoma; importantly, it is the first reported clinical product to target a protein on the surface of cancer cells called…

More...

Patrys PAT-SM6 shows promise in multiple myeloma

In September 2011, Patrys announced the results of preclinical work conducted at The University Hospital of Würzburg showing the activity of one of Patrys’ products in multiple myeloma.

More...

PAT-SM6 inhibits metastases in melanoma cancer model

In August 2011, Patrys announced positive results from a new proof-of-concept study on its lead product PAT-SM6 in an animal model. The study examined PAT-SM6’s activity against metastatic melanoma.

More...

PAT-SC1 shows significant survival benefit in gastric cancer trial

In September 2011, Patrys announced positive results from a follow-up of gastric cancer patients who were treated with anti-cancer compound PAT-SC1.

More...

Welcome to Patrys

Patrys is a publicly-listed company on the Australian Securities Exchange (ASX:PAB). Our principal focus is on the development of a completely new type of product for the treatment of cancer – natural human antibodies. These natural human antibodies offer the promise of increased potency coupled with greater safety as compared to existing cancer treatments.